Delaware
|
95-4405754
|
(State
or Other Jurisdiction of
|
(I.R.S.
Employer
|
Incorporation
or Organization)
|
Identification
No.)
|
500 Newport Center
Drive, Newport Beach,
CA
|
92660
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Large
accelerated filer ¨
|
Accelerated
filer þ
|
Non-accelerated
filer ¨ (Do not check if
a smaller reporting company)
|
Smaller
reporting company ¨
|
Part
I. Financial Information
|
||
Item
1.
|
Financial
Statements
|
|
Consolidated Balance Sheets as of
June 30, 2008 and December
31, 2007 (Unaudited)
|
1
|
|
Consolidated Statements of
Operations and Comprehensive Income (Loss) for the
Three Months and Six Months Ended
June 30, 2008 and 2007 (Unaudited)
|
2
|
|
Consolidated Statements of Cash
Flows for the Six Months Ended
June 30, 2008 and 2007
(Unaudited)
|
3
|
|
Notes to Consolidated Financial
Statements (Unaudited)
|
4
|
|
Item
2.
|
Management’s Discussion and
Analysis of Financial Condition and Results
of Operations
|
11
|
Item
3.
|
Quantitative and Qualitative
Disclosures About Market Risk
|
18
|
Item
4.
|
Controls and
Procedures
|
18
|
Part
II. Other Information
|
||
Item
1.
|
Legal Proceedings
|
19
|
Item
1A.
|
Risk Factors
|
19
|
Item
4.
|
Submission of Matters to a Vote
of Security Holders
|
20
|
Item
6.
|
Exhibits
|
21
|
Signatures
|
22
|
|
Exhibit
Index
|
23
|
June
30,
|
December
31,
|
|||||||
2008
|
2007
|
|||||||
ASSETS
|
||||||||
Current
assets:
|
||||||||
Cash
and cash equivalents
|
$ | 41,059 | $ | 40,467 | ||||
Short-term
investments
|
2,151 | 10,966 | ||||||
Accounts
receivable
|
4,386 | 1,409 | ||||||
Prepaid
expenses and other current assets
|
1,381 | 1,356 | ||||||
Total
current assets
|
48,977 | 54,198 | ||||||
Property
and equipment, net of accumulated depreciation
|
281 | 323 | ||||||
Patents,
net of accumulated amortization
|
15,386 | 16,307 | ||||||
Investments
- noncurrent
|
2,537 | - | ||||||
Other
assets
|
224 | 223 | ||||||
$ | 67,405 | $ | 71,051 | |||||
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
||||||||
Current
liabilities:
|
||||||||
Accounts
payable and accrued expenses
|
$ | 2,915 | $ | 3,462 | ||||
Royalties
and contingent legal fees payable
|
4,881 | 2,343 | ||||||
Deferred
revenues
|
272 | 321 | ||||||
Total
current liabilities
|
8,068 | 6,126 | ||||||
Other
liabilities
|
153 | 121 | ||||||
Total
liabilities
|
8,221 | 6,247 | ||||||
Commitments
and contingencies (Note 6)
|
||||||||
Stockholders'
equity:
|
||||||||
Preferred
stock
|
||||||||
Acacia
Research Corporation preferred stock, par value $0.001 per share;
10,000,000
|
||||||||
shares
authorized; no shares issued or outstanding
|
- | - | ||||||
Common
stock
|
||||||||
Acacia
Research Corporation common stock, par value $0.001 per
share;
|
||||||||
100,000,000
shares authorized; 30,937,327 and 30,102,482 shares issued
and
|
||||||||
outstanding
as of June 30, 2008 and December 31, 2007, respectively
|
30 | 30 | ||||||
Additional
paid-in capital
|
163,881 | 159,972 | ||||||
Accumulated
comprehensive income
|
(2 | ) | (3 | ) | ||||
Accumulated
deficit
|
(104,725 | ) | (95,195 | ) | ||||
Total
stockholders' equity
|
59,184 | 64,804 | ||||||
$ | 67,405 | $ | 71,051 |
For
the Three Months Ended
|
For
the Six Months Ended
|
|||||||||||||||
June
30, 2008
|
June
30, 2007
|
June
30, 2008
|
June
30, 2007
|
|||||||||||||
License
fee revenues
|
$ | 7,116 | $ | 5,865 | $ | 16,164 | $ | 31,050 | ||||||||
Operating
expenses:
|
||||||||||||||||
Marketing, general and
administrative expenses (including non-cash stock compensation
expense of $1,938 and $3,767 for the three and six months ended
June 30, 2008 and $1,144 and $1,907 for the three and six months ended
June 30, 2007)
|
5,947 | 4,190 | 12,573 | 8,518 | ||||||||||||
Inventor
royalties and contingent legal fees expense - patents
|
4,105 | 3,406 | 8,836 | 17,528 | ||||||||||||
Legal
expenses - patents
|
1,073 | 1,069 | 2,089 | 2,436 | ||||||||||||
Amortization
of patents
|
1,244 | 1,314 | 2,579 | 2,630 | ||||||||||||
Total
operating expenses
|
12,369 | 9,979 | 26,077 | 31,112 | ||||||||||||
Operating
loss
|
(5,253 | ) | (4,114 | ) | (9,913 | ) | (62 | ) | ||||||||
Other
income (expense):
|
||||||||||||||||
Interest
income
|
238 | 650 | 693 | 1,057 | ||||||||||||
Loss
on investments
|
- | - | (263 | ) | - | |||||||||||
Total
other income (expense)
|
238 | 650 | 430 | 1,057 | ||||||||||||
Income
(loss) from continuing operations before income taxes
|
(5,015 | ) | (3,464 | ) | (9,483 | ) | 995 | |||||||||
Provision
for income taxes
|
(26 | ) | (124 | ) | (47 | ) | (148 | ) | ||||||||
Income
(loss) from continuing operations
|
(5,041 | ) | (3,588 | ) | (9,530 | ) | 847 | |||||||||
Discontinued
operations:
|
||||||||||||||||
Loss
from discontinued operations - Split-off of CombiMatrix
Corporation
|
- | (3,667 | ) | - | (5,800 | ) | ||||||||||
Net
loss
|
(5,041 | ) | (7,255 | ) | (9,530 | ) | (4,953 | ) | ||||||||
Unrealized
gain (loss) on short-term investments
|
2 | (10 | ) | 1 | (18 | ) | ||||||||||
Unrealized
gain on foreign currency translation
|
- | 1 | - | 1 | ||||||||||||
Unrealized
gain from discontinued operations - Split-off of CombiMatrix
Corporation
|
- | 1 | - | 10 | ||||||||||||
Comprehensive
loss
|
$ | (5,039 | ) | $ | (7,263 | ) | $ | (9,529 | ) | $ | (4,960 | ) | ||||
Income
(loss) per common share:
|
||||||||||||||||
Acacia
Research - Acacia Technologies stock:
|
||||||||||||||||
Net
income (loss)
|
$ | (5,041 | ) | $ | (3,588 | ) | $ | (9,530 | ) | $ | 847 | |||||
Basic
earnings (loss) per share
|
(0.17 | ) | (0.13 | ) | (0.33 | ) | 0.03 | |||||||||
Diluted
earnings (loss) per share
|
(0.17 | ) | (0.13 | ) | (0.33 | ) | 0.03 | |||||||||
Acacia
Research - CombiMatrix stock - Discontinued Operations - Split-off of
CombiMatrix Corporation:
|
||||||||||||||||
Loss
from discontinued operations - Split-off of CombiMatrix
Corporation
|
$ | - | $ | (3,667 | ) | $ | - | $ | (5,800 | ) | ||||||
Basic
and diluted loss per share
|
- | (0.06 | ) | - | (0.11 | ) | ||||||||||
Weighted
average shares:
|
||||||||||||||||
Acacia
Research - Acacia Technologies stock:
|
||||||||||||||||
Basic
|
29,321,176 | 28,298,328 | 29,269,713 | 28,071,069 | ||||||||||||
Diluted
|
29,321,176 | 28,298,328 | 29,269,713 | 31,064,677 | ||||||||||||
Acacia
Research - CombiMatrix stock:
|
||||||||||||||||
Basic
and diluted
|
- | 57,143,839 | - | 54,842,813 |
For
the Six Months Ended
|
|||||||||
June
30, 2008
|
June
30, 2007
|
||||||||
Cash
flows from operating activities:
|
|||||||||
Net
loss
|
$ | (9,530 | ) | $ | (4,953 | ) | |||
Adjustments
to reconcile net loss to net cash provided by (used in)
operating
|
|||||||||
activities
from continuing operations:
|
|||||||||
Discontinued
operations - Split-off of CombiMatrix Corporation
|
- | 5,800 | |||||||
Depreciation
and amortization
|
2,645 | 2,687 | |||||||
Non-cash
stock compensation
|
3,767 | 1,907 | |||||||
Loss
on investments
|
263 | - | |||||||
Other
|
4 | (21 | ) | ||||||
Changes
in assets and liabilities:
|
|||||||||
Accounts
receivable
|
(2,977 | ) | (1,911 | ) | |||||
Prepaid
expenses and other assets
|
(26 | ) | (220 | ) | |||||
Accounts
payable and accrued expenses
|
(517 | ) | (82 | ) | |||||
Royalties
and contingent legal fees payable
|
2,538 | 492 | |||||||
Deferred
revenues
|
(49 | ) | (109 | ) | |||||
Net
cash provided by (used in) operating activities from continuing
operations
|
(3,882 | ) | 3,590 | ||||||
Net
cash provided by (used in) operating activities from discontinued
operations
|
2 | (6,679 | ) | ||||||
Net
cash used in operating activities
|
(3,880 | ) | (3,089 | ) | |||||
Cash
flows from investing activities:
|
|||||||||
Purchase
of property and equipment
|
(23 | ) | (160 | ) | |||||
Purchase
of available-for-sale investments
|
(265 | ) | (5,477 | ) | |||||
Sale
of available-for-sale investments
|
6,277 | 2,959 | |||||||
Patent
acquisition costs
|
(1,659 | ) | (1,395 | ) | |||||
Net
cash provided by (used in) investing activities from continuing
operations
|
4,330 | (4,073 | ) | ||||||
Net
cash used in investing activities from discontinued
operations
|
- | (3,960 | ) | ||||||
Net
cash provided by (used in) investing activities
|
4,330 | (8,033 | ) | ||||||
Cash
flows from financing activities:
|
|||||||||
Proceeds
from the exercise of stock options
|
142 | 3,159 | |||||||
Net
cash provided by financing activities from continuing
operations
|
142 | 3,159 | |||||||
Net
cash provided by financing activities from discontinued
operations
|
- | 5,369 | |||||||
Net
cash provided by financing activities
|
142 | 8,528 | |||||||
Increase
(decrease) in cash and cash equivalents
|
592 | (2,594 | ) | ||||||
Cash
and cash equivalents, beginning (including cash and cash equivalents
related to discontinued
|
|||||||||
operations
- split-off of CombiMatrix Corporation of $7,829 at December 31,
2006)
|
40,467 | 40,044 | |||||||
Cash
and cash equivalents, ending
|
41,059 | 37,450 | |||||||
Less:
Cash and cash equivalents of discontinued operations,
ending
|
- | (2,383 | ) | ||||||
Cash
and cash equivalents of continuing operations, ending
|
$ | 41,059 | $ | 35,067 |
For
the Three Months Ended
|
For
the Six Months Ended
|
|||||||||||||||
June
30, 2008
|
June
30, 2007
|
June
30, 2008
|
June
30, 2007
|
|||||||||||||
Acacia Research
Corporation common stock
(2)
|
||||||||||||||||
Basic
weighted average number of common shares outstanding
|
29,321,176 | 28,298,328 | 29,269,713 | 28,071,069 | ||||||||||||
Effect
of dilutive stock options and restricted stock awards
|
- | - | - | 2,993,607 | ||||||||||||
Diluted
weighted average number of common shares outstanding
|
29,321,176 | 28,298,328 | 29,269,713 | 31,064,677 | ||||||||||||
Outstanding
stock options, nonvested restricted stock and restricted stock units
excluded from the computation of diluted loss
per share because the effect of inclusion would have been
anti-dilutive
|
6,125,010 | 6,170,926 | 6,125,010 | 2,008,176 | ||||||||||||
Acacia Research - CombiMatrix stock -
Discontinued Operations - Split-off of CombiMatrix Corporation(1)
|
||||||||||||||||
Basic
and diluted weighted average number of common shares
outstanding
|
- | 57,143,839 | - | 54,842,813 | ||||||||||||
Outstanding
stock options and warrants excluded from the computation of diluted loss
per share because the effect
of inclusion would have been anti-dilutive
|
- | 30,911,753 | - | 30,911,753 |
|
(1)
|
Reflects
activity and amounts outstanding as of the Redemption
Date.
|
|
(2)
|
Refer to Note 1 for information
on the May 2008 Amendment and Restatement of Acacia Research
Corporation’s
Certificate of Incorporation
|
Fair Value Measurements at Reporting Date
Using:
|
||||||||||
Quoted
Prices in
|
Significant
Other
|
Significant
|
||||||||
Balance
at
|
Active
Markets
|
Observable
|
Unobservable
|
|||||||
June
30,
|
For
Identical Assets
|
Inputs
|
Inputs
|
|||||||
Description
|
2008
|
(Level 1)
|
(Level 2)
|
(Level 3)
|
||||||
Auction
rate securities
|
$
|
4,687
|
-
|
-
|
$
|
4,687
|
Fair Value
Measurements Using
Significant Unobservable Inputs (Level 3)
|
||||
Auction rate
securities:
|
||||
Balance
at December 31, 2007
|
$ | - | ||
Transfers
to Level 3
|
6,000 | |||
Total
gains or (losses) (realized or unrealized):
|
||||
Included
in earnings
|
(263 | ) | ||
Included
in other comprehensive income
|
- | |||
Purchases
and settlements (net)
|
(1,050 | ) | ||
Balance
at June 30, 2008
|
$ | 4,687 |
|
·
|
Surgical
Catheter. This patented technology generally relates to
surgical devices, such as percutaneously insertable catheters and
cannulas, that are used to access the circulatory system. These devices
can be used in cardiology and other surgical
procedures.
|
|
·
|
Vehicle Maintenance
Systems. This patented technology generally relates to vehicle
maintenance alerts. This technology may be used to alert a driver
that an oil change or other vehicle maintenance should be
performed.
|
|
·
|
Online Ad
Tracking. This patented technology generally relates to
tracking advertising usage on a network such as the Internet. For example,
this technology can be used to track click through rates of web site
advertising.
|
|
·
|
Videoconferencing. This
patented technology relates to videoconferencing systems and services
based on the Internet.
|
|
·
|
Laparoscopic
Surgery. The patented
technology relates to devices used by surgeons to help repair broken
or damaged blood vessels or gastrointestinal organs. The
devices can be used by cardiologists, gastrointestinal
specialists, and other medical
professionals.
|
|
·
|
Microprocessor. This
patented technology relates to the execution of
instructions by a processor and has applications in personal
computers, servers and embedded
processors.
|
|
·
|
Interactive TV.
This patented technology generally relates to recording interactive
TV responses to specific broadcast material from specific users. This
technology can be used by advertisers to evaluate current advertisement
effectiveness and target buyers with future advertisements. This
technology can also be used by interactive television companies to study
subscriber viewing and interactivity
behavior.
|
|
·
|
Internet Radio Advertisement.
This patented technology generally relates
to advertisement replacement for Internet radio. This technology can
be used by radio stations to replace broadcast advertisements for
distribution over the Internet.
|
|
·
|
Improved Printing. This
patented technology generally relates to patents relating to
improving print quality based on stochastic screening. This
technology renders finer detail and eliminates artifacts found in
traditional halftone patterns. High-volume, commercial printers,
newspapers and publishers can use this technology to improve print quality
while cutting cost.
|
|
·
|
Enterprise Content
Management. This patented technology generally relates to
categorization and sharing of information within an organization and can
be used to organize Internet links, electronic files and hardcopy
documents.
|
For
the Three Months Ended
|
For
the Six Months Ended
|
|||||||||||||||
June
30, 2008
|
June
30, 2007
|
June
30, 2008
|
June
30, 2007
|
|||||||||||||
Income
(loss) from continuing operations
|
$ | (5,041 | ) | $ | (3,588 | ) | $ | (9,530 | ) | $ | 847 | |||||
Loss
from discontinued operations - Split-off of CombiMatrix Corporation and
other
|
- | (3,667 | ) | - | (5,800 | ) | ||||||||||
Net
income (loss)
|
$ | (5,041 | ) | $ | (7,255 | ) | $ | (9,530 | ) | $ | (4,953 | ) |
For
the Three Months Ended
|
For
the Six Months Ended
|
|||||||||||||||
June
30, 2008
|
June
30, 2007
|
June
30, 2008
|
June
30, 2007
|
|||||||||||||
License
fees
|
$ | 7,116 | $ | 5,865 | $ | 16,164 | $ | 31,050 |
|
·
|
the
dollar amount of agreements executed each period, which is primarily
driven by the nature and characteristics of the technology being licensed
and the magnitude of infringement associated with a specific
licensee;
|
|
·
|
the
specific terms and conditions of agreements executed each period and the
periods of infringement contemplated by the respective
payments;
|
|
·
|
fluctuations
in the total number of agreements
executed;
|
|
·
|
fluctuations
in the sales results or other royalty per unit activities of our licensees
that impact the calculation of license fees
due;
|
|
·
|
the
timing of the receipt of periodic license fee payments and/or reports from
licensees; and
|
|
·
|
fluctuations
in the net number of active licensees period to
period.
|
For
the Three Months Ended
|
For
the Six Months Ended
|
|||||||||||||||
June
30, 2008
|
June
30, 2007
|
June
30, 2008
|
June
30, 2007
|
|||||||||||||
Marketing,
general and administrative expenses (including non-cash stock compensation
expense of
$1,938 and $3,767 for the three and six months ended June 30, 2008 and
$1,144 and $1,907 for the three and six months ended June 30,
2007)
|
$ | 5,947 | $ | 4,190 | $ | 12,573 | $ | 8,518 | ||||||||
Inventor
royalties and contingent legal fees expense - patents
|
4,105 | 3,406 | 8,836 | 17,528 | ||||||||||||
Legal
expenses - patents
|
1,073 | 1,069 | 2,089 | 2,436 |
For
the Three Months
|
For
the Six Months
|
|||||||
Ended
June 30,
|
Ended
June 30,
|
|||||||
2008
vs. 2007
|
2008
vs. 2007
|
|||||||
Addition
of licensing, business development and engineering personnel
|
$ | 374 | $ | 1,200 | ||||
One
time employee severance charges
|
231 | (129 | ) | |||||
Foreign
taxes paid on licensing fees
|
(6 | ) | (151 | ) | ||||
Business
development and licensing related patent research and consulting costs
|
202 | 1,001 | ||||||
Corporate,
general and administrative costs
|
162 | 348 | ||||||
Non-cash
stock compensation expense
|
794 | 1,860 | ||||||
Consulting
expenses paid to former CEO of Global Patent Holdings, LLC
|
- | (74 | ) |
For
the Six Months Ended
|
||||||||
June
30, 2008
|
June
30, 2007
|
|||||||
Net
cash provided by (used in) continuing operations:
|
||||||||
Operating
activities
|
$ | (3,882 | ) | $ | 3,590 | |||
Investing
activities
|
4,330 | (4,073 | ) | |||||
Financing
activities
|
142 | 3,159 |
Payments
Due by Period (in thousands)
|
||||||||||||||||||||||||||||
Contractual
Obligations
|
Remaining
|
2013
and
|
||||||||||||||||||||||||||
Total
|
2008
|
2009
|
2010
|
2011
|
2012
|
Thereafter
|
||||||||||||||||||||||
Operating
leases
|
$3,345
|
$363
|
$903
|
$939
|
$977
|
$163
|
$
-
|
|||||||||||||||||||||
Total
contractual cash obligations
|
$3,345
|
$363
|
$903
|
$939
|
$977
|
$163
|
$
-
|
Name
|
For
|
Withheld
|
Edward
W. Frykman
|
20,340,929
|
1,185,719
|
William
S. Anderson
|
20,932,008
|
594,640
|
For
|
Against
|
Abstain
|
21,228,244
|
288,221
|
10,183
|
For
|
Against
|
Abstain
|
21,384,700
|
132,630
|
9,318
|
3.1
|
Amended
and Restated Certificate of Incorporation filed with the California
Secretary of State on June 3, 2008 (1)
|
31.1
|
Certifications
of the Chief Executive Officer provided pursuant to Rule
13a-14(a)/15d-14(a) of the Securities Exchange Act of
1934
|
31.2
|
Certifications
of the Chief Financial Officer provided pursuant to Rule
13a-14(a)/15d-14(a) of the Securities Exchange Act of
1934
|
32.1
|
Certifications
of the Chief Executive Officer provided pursuant to Rule
13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C.
Section 1350
|
32.2
|
Certifications
of the Chief Financial Officer provided pursuant to Rule
13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C.
Section 1350
|
|
(1)
|
Incorporated
by reference to Acacia Research Corporation’s Report on Form 8-K filed
with the SEC on June 5, 2008 (SEC File No.
000-026068).
|
ACACIA
RESEARCH CORPORATION
|
|||
|
By:
|
/s/ Paul R. Ryan | |
Paul
R. Ryan
Chief
Executive Officer
(Authorized
Signatory)
|
|
By:
|
/s/ Clayton J. Haynes | |
Clayton
J. Haynes
Chief
Financial Officer /Treasurer
(Principal
Financial Officer)
|
EXHIBIT
NUMBER
|
EXHIBIT |
3.1
|
Amended
and Restated Certificate of Incorporation filed with the California
Secretary of State on June 3, 2008 (1)
|
31.1
|
Certifications
of the Chief Executive Officer provided pursuant to Rule
13a-14(a)/15d-14(a) of the Securities Exchange Act of
1934
|
31.2
|
Certifications
of the Chief Financial Officer provided pursuant to Rule
13a-14(a)/15d-14(a) of the Securities Exchange Act of
1934
|
32.1
|
Certifications
of the Chief Executive Officer provided pursuant to Rule
13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C.
Section 1350
|
32.2
|
Certifications
of the Chief Financial Officer provided pursuant to Rule
13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C.
Section 1350
|
|
(1)
|
Incorporated
by reference to Acacia Research Corporation’s Report on Form 8-K filed
with the SEC on June 5, 2008 (SEC File No.
000-026068).
|